Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks
Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks
复制标题
DOI：
10.1038/s41390-019-0438-0
复制
发表时间：
2019-09-01
影响因子：
3.6
通讯作者：
Lodish, Maya
中科院分区：
文献类型：
--
作者：
Makri, Angeliki;Cheung, Anita;Lodish, Maya
背景技术背景：心血管（CV）并发症是成人库欣病（CD）患者死亡的最重要原因;对CD儿童的CV风险因素知之甚少。通过核磁共振（NMR）光谱测量脂蛋白颗粒是评估CV风险的新技术。本研究的目的是分析儿童CD患者缓解前和缓解后1年的NMR血脂谱。方法：使用Vantera NMR分析仪获得33例CD患者的冷冻血清样本的NMR血脂谱（平均年龄13.8 +/- 4.0岁）在1997年至2017年期间在美国国立卫生研究院（NIH）临床中心（CC）进行评估。GlycA（糖基化急性时相蛋白），富含谷胱甘肽的颗粒（TRLP中等和非常小的尺寸），低密度脂蛋白（LDL）颗粒（总LDLP和大尺寸），高密度脂蛋白（HDL）颗粒（HDLP总、中等和小尺寸）、总胆固醇、LDL-胆固醇、HDL-胆固醇、GlycA炎症生物标志物，CD缓解后载脂蛋白B和载脂蛋白A1（ApoA 1）浓度变化有统计学意义（p < 0.05）。结论：在我们的研究人群中，除了HDL和ApoA 1外，大多数血脂变量在CD缓解后改善，表明NMR脂蛋白谱可能是评估儿童CD患者CV风险的有用工具。
BACKGROUND: Cardiovascular (CV) complications are the most significant cause of mortality in adults with Cushing disease (CD); little is known about CV risk factors in children with CD. Measurement of lipoprotein particles by nuclear magnetic resonance (NMR) spectroscopy is a novel technology to assess CV risk. The objective of the current study is to analyze the NMR lipid profile in pediatric CD patients before and 1 year after remission.METHODS: NMR lipid profile was obtained via the Vantera NMR analyzer, using frozen serum samples from 33 CD patients (mean age 13.8 +/- 4.0 years) evaluated between 1997 and 2017 at the National Institutes of Health (NIH) Clinical Center (CC).RESULTS: GlycA (glycosylated acute-phase proteins), triglyceride-rich particles (TRLP medium and very small sizes), low-density lipoprotein (LDL) particles (LDLP total and large size), high-density lipoprotein (HDL) particles (HDLP total, medium and small sizes), total cholesterol, LDL-cholesterol, HDL-cholesterol, GlycA inflammatory biomarker, and apolipoprotein B and apolipoprotein A1 (ApoA1) concentrations showed statistically significant changes after remission of CD (p < 0.05).CONCLUSION: In our study population, most of the lipid variables improved post-CD remission, with the exception of HDL and ApoA1, indicating that NMR lipoprotein profile may be a helpful tool in assessing the CV risk in pediatric patients with CD.